Pharmacokinetic Analysis of Gatifloxacin in Plasma and Sinus Aspirate During Treatment of Acute Maxillary Sinusitis

Pharmacokinetic Analysis of Gatifloxacin in Plasma and Sinus Aspirate During Treatment of Acute Maxillary Sinusitis

Conference: AAPS

A novel approach to collect sinus exudate was utilized and the time course of gatifloxacin (GAT) in the blood and at the primary infection site were assessed during treatment for acute maxillary sinusitis (AMS).

Comparison of Parametric (NONMEM®) and Non-Parametric (NPEM®) Methods for Population Pharmcokinetic Modeling of Bi-Model Populations

Comparison of Parametric (NONMEM®) and Non-Parametric (NPEM®) Methods for Population Pharmcokinetic Modeling of Bi-Model Populations

Conference: AAPS

Debate exists whether the most appropriate population analysis method is parametric (NONMEM®) or non-parametric (NPEM®), especially for data from a bi-modal population (i.e., poor/extensive metabolizers...

Gatifloxacin Exposure in Maxillary Sinus and Middle Ear – All Sites of Infection Are Not Created Equal

Gatifloxacin Exposure in Maxillary Sinus and Middle Ear – All Sites of Infection Are Not Created Equal

Conference: IDSA

Due to the similar physiology of maxillary sinus (MS) and middle ear (ME), it is often assumed that antimicrobial penetration is similar into MS and ME fluids. Traditional methods for assessing drug penetration…

Serial Sinus Aspirate Sampling (SSAS): A Novel Technique for Evaluating Antimicrobial Therapy of Acute Maxillary Sinusitis (AMS)

Serial Sinus Aspirate Sampling (SSAS): A Novel Technique for Evaluating Antimicrobial Therapy of Acute Maxillary Sinusitis (AMS)

Conference: ICAAC

The relationship between drug exposure and the time course of antimicrobial effect at the primary infection site for acute maxillary sinusitis has not previously been explored. Purpose. To quantify the time…

Relationship Between Increased Levofloxacin Use and Decreased Susceptibility of Streptococcus pneumoniae: Report From the ARREST Program

Relationship Between Increased Levofloxacin Use and Decreased Susceptibility of Streptococcus pneumoniae: Report From the ARREST Program

Conference: ICAAC

Increasing reports describing the emergence of quinolone nonsusceptible Streptococcus pneumoniae (SP) are of clinical concern. We examined the relationship between outpatient quinolone use and susceptibility…

Clinical pharmacodynamics of quinolones

Clinical pharmacodynamics of quinolones

Publication: Infect Dis Clin North Am

An understanding of fundamental PK-PD principles forms the basis for the rational use of antimicrobial agents. For quinolones, the fAUC24:MIC ratio is predictive of efficacy in animal and in vitro infection models, and in infected patients.

Relationships between patient and institution specific variables and decreased antimicrobial susceptibility of gram-negative pathogens

Relationships between patient and institution specific variables and decreased antimicrobial susceptibility of gram-negative pathogens

Publication: Clin Infect Dis

The identification of patients infected with antibiotic-resistant strains of bacteria for inclusion in clinical trials remains a serious challenge for the future development of agents for use against such infections.

You’ve Got Data! Using SAS from Data Receipt to Reporting

You’ve Got Data! Using SAS from Data Receipt to Reporting

Authors: Vecchione P
Conference: Pharmaceutical Industry SAS Users Group (PharmaSUG)

In a fast-paced, pharmaceutical data analysis environment, the transfer of data needs to be quick and accurate. A number of steps are involved in coordinating data transfers. Data must be…

Application of Real-Time Data Assembly (RTDA) to a Pivotal Phase III Pediatric Trial: A Proactive Approach to Population Pharmacokinetic/Pharmacodynamic (PK/PD) Dataset Creation

Application of Real-Time Data Assembly (RTDA) to a Pivotal Phase III Pediatric Trial: A Proactive Approach to Population Pharmacokinetic/Pharmacodynamic (PK/PD) Dataset Creation

Conference: ASCPT

To implement an RTDA process, similar to that described in the FDA Guidance for Industry: Population Pharmacokinetics, during a Phase III trial of linezolid (IV to oral) in pediatric patients which....